166 related articles for article (PubMed ID: 35769513)
1. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.
Zhu L; Zhou KX; Ma MZ; Yao LL; Zhang YL; Li H; Du C; Yang XM
J Immunol Res; 2022; 2022():1590717. PubMed ID: 35769513
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA LINC01123 promotes the proliferation and invasion of hepatocellular carcinoma cells by modulating the miR-34a-5p/TUFT1 axis.
Xiao Z; Liu Y; Zhao J; Li L; Hu L; Lu Q; Zeng Z; Liu X; Huang D; Yang W; Xu Q
Int J Biol Sci; 2020; 16(13):2296-2305. PubMed ID: 32760198
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth.
Wu MN; Zheng WJ; Ye WX; Wang L; Chen Y; Yang J; Yao DF; Yao M
World J Gastroenterol; 2021 Jun; 27(23):3327-3341. PubMed ID: 34163115
[TBL] [Abstract][Full Text] [Related]
4. [Effect of TUTF1 expression on the proliferation, apoptosis and prognosis of hepatocellular carcinoma cells].
Li ZJ; Li JS; Li DY; Pu T
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):879-884. PubMed ID: 31941243
[No Abstract] [Full Text] [Related]
5. [Overexpression of tuftelin and KLF-5 and its clinicopathological features in hepatitis B virus-related hepatocellular carcinoma].
Yang JL; Fang RF; Xie Q; Tai BJ; Yao DF; Yao M
Zhonghua Gan Zang Bing Za Zhi; 2024 Feb; 32(2):148-154. PubMed ID: 38514264
[No Abstract] [Full Text] [Related]
6. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
7. [Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues].
Wu MN; Yang JL; Shen SJ; Wang L; Zheng WJ; Wu W; Yao M; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):338-343. PubMed ID: 33979960
[No Abstract] [Full Text] [Related]
8. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma
Lin H; Zeng W; Lei Y; Chen D; Nie Z
Pathol Oncol Res; 2021; 27():640936. PubMed ID: 34257606
[TBL] [Abstract][Full Text] [Related]
9. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.
Feng T; Li S; Zhao G; Li Q; Yuan H; Zhang J; Gu R; Ou D; Guo Y; Kou Q; Wang Q; Li K; Lin P
Cell Oncol (Dordr); 2023 Oct; 46(5):1235-1252. PubMed ID: 37052853
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain-containing protein 9 promotes the growth and metastasis of human hepatocellular carcinoma by activating the TUFT1/AKT pathway.
Dou C; Sun L; Wang L; Cheng J; Wu W; Zhang C; Xu Q; Tu K; Liu J
Cell Death Dis; 2020 Sep; 11(9):730. PubMed ID: 32908135
[TBL] [Abstract][Full Text] [Related]
11. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
12. USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638.
Ni W; Lin S; Bian S; Zheng W; Qu L; Fan Y; Lu C; Xiao M; Zhou P
Cell Death Dis; 2020 Oct; 11(10):843. PubMed ID: 33040080
[TBL] [Abstract][Full Text] [Related]
13. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
15. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
[TBL] [Abstract][Full Text] [Related]
16. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARĪ± pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
17. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
18. Focal adhesion proteins in hepatocellular carcinoma: RSU1 a novel tumour suppressor with prognostic significance.
Geramoutsou C; Nikou S; Karavias D; Arbi M; Tavlas P; Tzelepi V; Lygerou Z; Maroulis I; Bravou V
Pathol Res Pract; 2022 Jul; 235():153950. PubMed ID: 35642986
[TBL] [Abstract][Full Text] [Related]
19. Role of hepatoma-derived growth factor in promoting deĀ novo lipogenesis and tumorigenesis in hepatocellular carcinoma.
Min X; Wen J; Zhao L; Wang K; Li Q; Huang G; Liu J; Zhao X
Mol Oncol; 2018 Sep; 12(9):1480-1497. PubMed ID: 30004626
[TBL] [Abstract][Full Text] [Related]
20. The histidine-rich calcium binding protein (HRC) promotes tumor metastasis in hepatocellular carcinoma and is upregulated by SATB1.
Liu J; Han P; Li M; Yan W; Liu J; Liu J; He J; Tu W; Xia Y; Zhou Z; Gong J; Liu M; Ding Q; Tian D
Oncotarget; 2015 Mar; 6(9):6811-24. PubMed ID: 25762622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
